Richard Abben, MD
Interventional Cardiology · Houma, LANPI 1750388740
Payments from drug & device makers
Across 406 payments — averaging $1188.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$405K
- Cvrx, Inc.$77K
- Endologix LLC$167
- Kestra Medical Technology Services, Inc.$165
- Abiomed$135
- Boehringer Ingelheim$95
- plus $410 from 14 others
Across 2 payments — averaging $2067.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$10,25010%
- Speaking & faculty fees$76,70076%
- Travel & lodging$9,1019%
- Food & beverage$5,2975%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 325 | $404,539 |
| Cvrx, Inc. | 26 | $77,135 |
| Endologix LLC | 1 | $167 |
| Kestra Medical Technology Services, Inc. | 9 | $165 |
| Abiomed | 15 | $135 |
| Boehringer Ingelheim | 7 | $95 |
| Pfizer | 3 | $58 |
| Johnson & Johnson | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| AstraZeneca | 2 | $34 |
| Boston Scientific | 2 | $34 |
| Amgen | 2 | $30 |
| Novartis | 2 | $29 |
| Abbott | 1 | $25 |
| Ablative Solutions, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Gilead | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$482,647 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,958 | $1,901,056 |
| EntrestoSacubitril/Valsartan | 442 | $533,256 |
| XareltoRivaroxaban | 491 | $465,618 |
| JardianceEmpagliflozin | 296 | $295,778 |
| Repatha SureclickEvolocumab | 226 | $200,724 |
| Repatha PushtronexEvolocumab | 137 | $109,018 |
| Praluent PenAlirocumab | 97 | $56,699 |
| FarxigaDapagliflozin Propanediol | 57 | $50,315 |
| CorlanorIvabradine Hcl | 43 | $37,104 |
| Acebutolol Hcl | 667 | $33,321 |
| Valsartan | 891 | $23,375 |
| Metoprolol Succinate | 1,709 | $22,899 |
| Atorvastatin Calcium | 2,148 | $21,708 |
| Dofetilide | 127 | $21,299 |
| Rosuvastatin Calcium | 1,714 | $20,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $1,901,0561,958 claims |
| NovartisEntresto | $29 | $533,256442 claims |
| Johnson & JohnsonXarelto | $47 | $465,618491 claims |
| Boehringer IngelheimJardiance | $95 | $295,778296 claims |
| AstraZenecaFarxiga | $34 | $50,31557 claims |
| AmgenCorlanor | $30 | $37,10443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Houma
- Craig WalkerHouma$5.5M
- Eric EngeronHouma$377K
- Pradeep NairHouma$220K
- Matthew FinnHouma$80K
- Anil ChagarlamudiHouma$27K
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
- James JenkinsNew Orleans$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.